蒲元和胃胶囊联合雷贝拉唑治疗反流性食管炎的临床评价  

Clinical evaluation of Puyuanhewei capsule combined with rabeprazole in treatment of reflux esophagitis

作　　者：闫莎莎[1] 马雪瑶 许园晨 张国瑜[1] Yan Sha-sha;Ma Xue-yao;Xu Yuan-chen;Zhang Guo-yu(Department of Thoracic Surgery,the First Affiliated Hospital of Henan University,Kaifeng 475000,China)

机构地区：[1]河南大学第一附属医院胸外科,开封475000

出　　处：《中国药物应用与监测》2024年第4期468-471,共4页Chinese Journal of Drug Application and Monitoring

基　　金：河南省二〇一九年科技发展计划项目(192102310107);河南省医学科技攻关计划项目(LHGJ20210552)。

摘　　要：目的 观察蒲元和胃胶囊联合雷贝拉唑治疗反流性食管炎的作用。方法 纳入河南大学第一附属医院胸外科2022年6月至2024年1月收治的102例反流性食管炎患者,以随机数字表法分成观察组(51例)与对照组(51例),给予对照组患者雷贝拉唑治疗,给予观察组患者蒲元和胃胶囊联合雷贝拉唑治疗,对比2组临床疗效、上腹痛、反酸与嗳气症状缓解时间、治疗前后反流性疾病问卷(RDQ)评分及胃动素、胃泌素水平以及不良反应情况。结果 观察组总有效率(96.08%)比对照组(84.31%)更高(χ^(2)=3.991,P<0.05);观察组患者的上腹痛、反酸与嗳气症状缓解时间分别为(6.15±0.52) d、(5.80±0.52) d、(5.52±0.38) d,均分别短于对照组患者(8.44±0.73) d、(7.38±0.66) d、(6.72±0.82) d,t=18.247、13.429、9.482,P<0.001;观察组患者治疗后症状发作频率评分为(3.99±0.52)分,症状发作程度评分为(5.48±0.69)分,均短于对照组治疗后评分(6.24±0.67)分、(7.42±0.72)分,t=18.946、13.893,P<0.001;观察组患者治疗后胃动素、胃泌素水平分别为(331.29±4.92) ng·L^(-1)、(178.54±4.37) pg·m L^(-1),均高于对照组(299.54±5.23) ng·L^(-1)、(143.25±4.92) pg·m L^(-1),t=31.577,P<0.001;观察组(3.92%)与对照组不良反应率(5.88%)差异无统计学意义,χ^(2)=0.210,P>0.05。结论 蒲元和胃胶囊结合雷贝拉唑治疗反流性食管炎效果良好,患者症状缓解快,胃肠功能恢复良好,治疗不良反应较少,值得应用。Objective To investigate the efficacy of Puyuanhewei capsule combined with rabeprazole in the treatment of reflux esophagitis.Methods A total of 102 patients with reflux esophagitis admitted to the First Affiliated Hospital of Henan University from June 2022 to January 2024 were divided into the observation group(n=51)and control group(n=51)by random number table method.Patients in the control group were given rabeprazole treatment while those in the observation group were given Puyuanhewei capsule combined with rabeprazole treatment.The efficacy,relief time of epigastric pain,pantothenic acid and belching symptoms were compared between the two groups.Reflux disease questionnaire(RDQ)score before and after treatment,levels of motilin and gastrin and treatment adverse reactions were also compared.Results The total effective rate was significantly higher in the observation group than in the control(96.08%vs 84.31%,χ^(2)=3.991 P<0.05).The relief time of epigastric pain,pantothenic acid and belching in the observation group were(6.15±0.52)d,(5.80±0.52)d and(5.52±0.38)d,respectively,which were shorter than those of(8.44±0.73)d,(7.38±0.66)d and(6.72±0.82)d in the control(t=18.247,13.429,9.482,P<0.001).Symptom frequency score and symptom severity score of the observation group were(3.99±0.52)points and(5.48±0.69)points after treatment and both of them were shorter than those of(6.24±0.67)points and(7.42±0.72)points of the control(t=18.946,13.893,P<0.001).After treatment,the levels of motilin and gastrin in observation group were(331.29±4.92)ng·L^(-1) and(178.54±4.37)pg.mL^(-1),respectively,which were lower than those of(299.54±5.23)ng·L^(-1) and(143.25±4.92)pg·mL^(-1) in the control(t=31.577,38.298,P<0.001).The adverse reaction rate of observation group was similar to that of the control(3.92%vs 5.88%,χ^(2)=0.210,P>0.05).Conclusion The combination of Puyuanhewei capsule with rabeprazole has a good effect in the treatment of reflux esophagitis since the symptoms of patients are relieved,the gastrointes

关 键 词：反流性食管炎 蒲元和胃胶囊 雷贝拉唑 疗效 症状缓解时间 反流性疾病问卷 不良反应 

分 类 号：R571[医药卫生—消化系统]